Search Results - David B. Solit

Refine Results
  1. 1
    Towards a Unified Model of RAF Inhibitor Resistance

    Towards a Unified Model of RAF Inhibitor Resistance by David B. Solit, Neal Rosen

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    KRAS and BRAF: drug targets and predictive biomarkers

    KRAS and BRAF: drug targets and predictive biomarkers by Efsevia Vakiani, David B. Solit

    Published 2010
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response by Christine A. Pratilas, David B. Solit

    Published 2010
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Targeting Oncogenic BRAF in Human Cancer

    Targeting Oncogenic BRAF in Human Cancer by Christine A. Pratilas, Feng Xing, David B. Solit

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged

    Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged by Paul B. Chapman, David B. Solit, Neal Rosen

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    ERK Pathway Inhibitors: How Low Should We Go?

    ERK Pathway Inhibitors: How Low Should We Go? by Moriah H. Nissan, Neal Rosen, David B. Solit

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Trametinib in Histiocytic Sarcoma with an Activating <i>MAP2K1</i> (MEK1) Mutation

    Trametinib in Histiocytic Sarcoma with an Activating <i>MAP2K1</i> (MEK1) Mutation by Mrinal M. Gounder, David B. Solit, William D. Tap

    Published 2018
    Get full text
    Carta
    Save to List
    Saved in:
  8. 8
    Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2

    Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 by Andrea Basso, David B. Solit, Pamela N. Münster, Neal Rosen

    Published 2002
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells

    Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells by Gil Redelman‐Sidi, Gopa Iyer, David B. Solit, Michael S. Glickman

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

    The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians by Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

    Published 2020
    Get full text
    Editorial
    Save to List
    Saved in:
  11. 11
    Clinical tumour sequencing for precision oncology: time for a universal strategy

    Clinical tumour sequencing for precision oncology: time for a universal strategy by Michael L. Cheng, Michael F. Berger, David M. Hyman, David B. Solit

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function

    Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function by Andrea Basso, David B. Solit, Gabriela Chiosis, Banabihari Giri, Philip N. Tsichlis, Neal Rosen

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

    V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors by Olivera M. Grbovic, Andrea Basso, Ayana Sawai, Q. Ye, Philip Friedlander, David B. Solit, Neal Rosen

    Published 2005
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway by Christine A. Pratilas, Barry S. Taylor, Qing Ye, Agnès Viale, Chris Sander, David B. Solit, Neal Rosen

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

    The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells by Qing‐Bai She, David B. Solit, Qing Ye, Kathryn E. O’Reilly, Jose Lobo, Neal Rosen

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors

    Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors by Seungchan Yang, Shimian Qu, Marianela Perez-Tores, Ayana Sawai, Neal Rosen, David B. Solit, Carlos L. Arteaga

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling

    PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling by Ensar Halilovic, Qing‐Bai She, Qing Ye, Raymond Pagliarini, William R. Sellers, David B. Solit, Neal Rosen

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

    Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel by David B. Solit, Yuhong She, Jose Lobo, Mark G. Kris, Howard I. Scher, Neal Rosen, Frank Sirotnak

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

    4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors by Qing‐Bai She, Ensar Halilovic, Qing Ye, Zhen Wei, Senji Shirasawa, Takehiko Sasazuki, David B. Solit, Neal Rosen

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials

    Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials by David M. Hyman, David B. Solit, Maria E. Arcila, Donavan T. Cheng, Paul Sabbatini, José Baselga, Michael F. Berger, Marc Ladanyi

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: